Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas

References

• Pohl O, Marchand L, Bell D, et al. Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding—delayed add-back onset does not improve bleeding pattern. Reprod Sci. 2020 Apr;27(4):988–995.
   PubMed Web of Science ®Google Scholar
• Lagana AS, Garzon S, Gotte M, et al. The pathogenesis of endometriosis: molecular and cell biology insights. Int J Mol Sci. 2019 Nov 10;20:22.
   Web of Science ®Google Scholar
• Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010 Jun 24;362(25):2389–2398.
   PubMed Web of Science ®Google Scholar
• Riemma G, Lagana AS, Schiattarella A, et al. Ion channels in the pathogenesis of endometriosis: a cutting-edge point of view. Int J Mol Sci. 2020 Feb 7;21:3.
   Web of Science ®Google Scholar
• Patel BG, Lenk EE, Lebovic DI, et al. Pathogenesis of endometriosis: interaction between Endocrine and inflammatory pathways. Best Pract Res Clin Obstet Gynaecol. 2018;50:50–60.
   PubMed Web of Science ®Google Scholar
• Garzon S, Lagana AS, Barra F, et al. Novel drug delivery methods for improving efficacy of endometriosis treatments. Expert Opin Drug Deliv. 2021 Mar;18(3):355–367.
   PubMed Web of Science ®Google Scholar
• Arnold J, Barcena de Arellano ML, Ruster C, et al. Imbalance between sympathetic and sensory innervation in peritoneal endometriosis. Brain Behav Immun. 2012 Jan;26(1):132–141.
   PubMed Web of Science ®Google Scholar
• Donnez J, Dolmans MM. Endometriosis and medical therapy: from progestogens to progesterone resistance to GnRH antagonists: a review. J Clin Med. 2021 Mar;10(5):5.
   Web of Science ®Google Scholar
• Garzon S, Lagana AS, Barra F, et al. Aromatase inhibitors for the treatment of endometriosis: a systematic review about efficacy, safety and early clinical development. Expert Opin Investig Drugs. 2020 Dec;29(12):1377–1388.
   PubMed Web of Science ®Google Scholar
• Liang Y, Yao S. Potential role of estrogen in maintaining the imbalanced sympathetic and sensory innervation in endometriosis. Mol Cell Endocrinol. 2016 Mar;424(424):42–49.
   PubMedGoogle Scholar
• As-Sanie S, Harris RE, Napadow V, et al. Changes in regional gray matter volume in women with chronic pelvic pain: a voxel-based morphometry study. Pain. 2012 May;153(5):1006–1014. .
   PubMed Web of Science ®Google Scholar
• Asiri MD, Banjar R, Al-Qahtani W, et al. Central Nervous System Changes in Pelvic Inflammation/Pain Patients. Curr Bladder Dysfunct Rep. 2019 Dec 01;14(4):223–230.
   Web of Science ®Google Scholar
• Barra F, Vitale SG, Seca M, et al. The potential role of elagolix for treating uterine bleeding associated to uterine myomas. Expert Opin Pharmacother. 2020 Aug;21(12):1419–1430. .
   PubMed Web of Science ®Google Scholar
• Donnez J, Arriagada P, Donnez O, et al. Emerging treatment options for uterine fibroids. Expert Opin Emerg Drugs. 2018 Mar;23(1):17–23.
   PubMed Web of Science ®Google Scholar
• Moravek MB, Yin P, Ono M, et al. Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications. Hum Reprod Update. 2015 Jan-Feb;21(1):1–12.
   PubMed Web of Science ®Google Scholar
• Schlaff WD, Ackerman RT, Al-Hendy A, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020 Jan 23;382(4):328–340.
   PubMed Web of Science ®Google Scholar
• Barra F, Scala C, Biscaldi E, et al. Ureteral endometriosis: a systematic review of epidemiology, pathogenesis, diagnosis, treatment, risk of malignant transformation and fertility. Hum Reprod Update.2018 Nov 1;24(6):710–730
   PubMed Web of Science ®Google Scholar
• Remorgida V, Ferrero S, Fulcheri E, et al. Bowel endometriosis: presentation, diagnosis, and treatment. Obstet Gynecol Surv. 2007 Jul;62(7):461–470.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opin Pharmacother. 2018 Jul;5:1–17.
   Google Scholar
• Perricos A, Wenzl R. Efficacy of elagolix in the treatment of endometriosis. Expert Opin Pharmacother. 2017 Sep;18(13):1391–1397.
   PubMed Web of Science ®Google Scholar
• Della Corte L, Barra F, Mercorio A, et al. Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis. Expert Opin Drug Metab Toxicol. 2020 Sep;16(9):759–768.
   PubMed Web of Science ®Google Scholar
• Lethaby A, Puscasiu L, Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. Cochrane Database Syst Rev. 2017 Nov;15(11):CD000547.
   Google Scholar
• FDA Drug Safety Communication: ongoing Safety Review of GnRH Agonists and possible increased risk of diabetes and certain cardiovascular diseases. [cited 2021 Jul 1]. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-ongoing-safety-review-gnrh-agonists-and-possible-increased-risk
   Google Scholar
• Ferrero S, Barra F. Leone Roberti Maggiore U. Current and emerging therapeutics for the management of endometriosis. Drugs. 2018 Jul;78(10):995–1012.
   PubMed Web of Science ®Google Scholar
• Zheng Q, Mao H, Xu Y, et al. Can postoperative GnRH agonist treatment prevent endometriosis recurrence? A meta-analysis. Arch Gynecol Obstet. 2016 Jul;294(1):201–207.
   PubMed Web of Science ®Google Scholar
• Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1992 Feb;166(2):740–745.
   PubMed Web of Science ®Google Scholar
• Pohl O, Marchand L, Fawkes N, et al. Gonadotropin-releasing hormone receptor antagonist mono- and combination therapy with estradiol/norethindrone acetate add-back: pharmacodynamics and safety of OBE2109. J Clin Endocrinol Metab. 2018 Feb 1;103(2):497–504.
   PubMed Web of Science ®Google Scholar
• Riggs MM, Bennetts M, van der Graaf PH, et al. Integrated pharmacometrics and systems pharmacology model-based analyses to guide GnRH receptor modulator development for management of endometriosis. CPT Pharmacometrics Syst Pharmacol. 2012 Oct;17(1):e11.
   Google Scholar
• Ezzati M, Carr BR. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond). 2015 Jan;11(1):19–28.
   PubMedGoogle Scholar
• Lamb YN. Elagolix: first Global Approval. Drugs. 2018 Sep;78(14):1501–1508.
   PubMed Web of Science ®Google Scholar
• Barra F, Scala C, Ferrero S. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain. Drugs Today (Barc). 2019 Apr;55(4):237–246.
   PubMed Web of Science ®Google Scholar
• Barra F, Seca M, Della Corte L, et al. Relugolix for the treatment of uterine fibroids. Drugs Today (Barc). 2019 Aug;55(8):503–512.
   PubMed Web of Science ®Google Scholar
• INN Recommended List 78. [cited 2021 Jul 1]. Available from: https://www.who.int/publications/m/item/inn-rl-78
   Google Scholar
• Kissei Pharmaceutical Co. L. Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof. WO2007046392A1. 2017.
   Google Scholar
• 城一道 秀. Salt of fused heterocyclic derivative and crystal thereof. WO2011099507A1. 2011.
   Google Scholar
• Goenka L, George M, Sen M. A peek into the drug development scenario of endometriosis - A systematic review. Biomed Pharmacothe. 2017 Jun;90:575–585.
   PubMed Web of Science ®Google Scholar
• Felberbaum RE, Ludwig M, Diedrich K. Clinical application of GnRH-antagonists. Mol Cell Endocrinol. 2000 Aug 15;166(1):9–14.
   PubMed Web of Science ®Google Scholar
• Donnez J, Taylor HS, Taylor RN, et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril. 2020 Jul;114(1):44–55.
   PubMed Web of Science ®Google Scholar
• Financial reports. ObsEva. Available from: www.obseva.com/financial-reports
   Google Scholar
• NCT02778399 - A randomized, double-blind, placebo-controlled, phase 2b dose-ranging study to assess the efficacy and safety of OBE2109 in subjects with endometriosis associated pain (EDELWEISS). clinicaltrialsgov. 2019.
   Google Scholar
• Taylor R, Bestel E, Gotteland J-P, et al. Long term treatment of endometriosis associated pain (EAP) with linzagolix: efficacy and safety after 12 months of treatment. Fertil Steril. 2019;09/01;112:e323.
   Web of Science ®Google Scholar
• Bestel E, Gotteland J-P, Donnez J, et al. Quality of life results after 52 weeks of treatment with linzagolix for endometriosis-associated pain [30B]. Obstetrics Gynecol. 2020 May 01;135:26S–27S.
   Web of Science ®Google Scholar
• Bestel E, Humberstone A, Lecomte V, et al. The Effect of Linzagolix on Bone Mineral Density (BMD): safety Results From a Dose-Ranging Trial [21J]. Obstetrics Gynecol. 2019 May 01;133:112S–113S.
   Web of Science ®Google Scholar
• NCT01533532 - A Multicenter, Randomized, Placebo-controlled, Double-blind Phase II Study of KLH-2109 in Patients With Endometriosis. clinicaltrialsgov. 2014.
   Google Scholar
• NCT03070899 - A phase 3, multicentre, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add-back therapy for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women (PRIMROSE 1). clinicaltrialsgov. 2020.
   Google Scholar
• NCT03070951 - A phase 3, multicentre, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add-back therapy for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women (PRIMROSE 2) clinicaltrialsgov. 2021.
   Google Scholar
• Bradley LD, Marsh EE, Garner E. Linzagolix may address the long-term treatment needs of women with uterine fibroids (UF) Who have contraindications to hormonal add-back therapy (ABT): results from two phase 3 randomized clinical trials. Fertil Steril. 2020;114(3):e527.
   Web of Science ®Google Scholar
• Donnez J, Dolmans MM. Fibroids and medical therapy: bridging the gap from selective progesterone receptor modulators to gonadotropin-releasing hormone antagonist. Fertil Steril. 2020 Oct;114(4):739–741.
   PubMed Web of Science ®Google Scholar
• Donnez O, Donnez J. Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis. Fertil Steril. 2020 Sep;114(3):640–645.
   PubMed Web of Science ®Google Scholar
• Bestel E, Gotteland J-P, Donnez J, et al. Linzagolix for endometriosis-associated pain: lipid changes after 52 weeks of treatment [25B]. Obstetrics Gynecol. 2020;135.• This abstract reports the results of the EDELWEISS study on lipid profile. 2020; 135\(Suppl 1):25S–25S
   Google Scholar
• As-Sanie S, Black R, Giudice LC, et al. Assessing research gaps and unmet needs in endometriosis. Am J Obstet Gynecol. 2019 Aug;221(2):86–94.
   PubMed Web of Science ®Google Scholar
• Osuga Y, Seki Y, Tanimoto M, et al. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2021 Feb;115(2):397–405.
   PubMed Web of Science ®Google Scholar
• FDA NEWS RELEASE. FDA approves new option to treat heavy menstrual bleeding associated with fibroids in women. [cited 2021 Jul 1]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-option-treat-heavy-menstrual-bleeding-associated-fibroids-women
   Google Scholar
• Osuga Y, Enya K, Kudou K, et al. Oral gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2019 Mar;133(3):423–433.
   PubMed Web of Science ®Google Scholar
• Osuga Y, Enya K, Kudou K, et al. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women. Fertil Steril. 2019 Nov;112(5):922–929 e2.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Vigano P, Barbara G, et al. Elagolix for endometriosis: all that glitters is not gold. Hum Reprod. 2019 Feb 1;34(2):193–199.
   PubMed Web of Science ®Google Scholar